-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ESQiHq6vXSbX/NsBnuDD3Jx2V2wKeF9O+hxRzoAcwqxEamTqf4qu9qUQ5Yn+rLD/ CtOU3AdsfEmOqzXIQr73HA== 0000897069-09-001065.txt : 20090618 0000897069-09-001065.hdr.sgml : 20090617 20090618122546 ACCESSION NUMBER: 0000897069-09-001065 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090616 FILED AS OF DATE: 20090618 DATE AS OF CHANGE: 20090618 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SABEL IVAN R CENTRAL INDEX KEY: 0001217563 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10670 FILM NUMBER: 09898286 MAIL ADDRESS: STREET 1: TWO BETHESDA METRO CENTER SUITE 1200 CITY: BETHESDA STATE: MD ZIP: 20814 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HANGER ORTHOPEDIC GROUP INC CENTRAL INDEX KEY: 0000722723 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 840904275 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: TWO BETHESDA METRO CENTER STREET 2: SUITE 1300 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: 3019860701 MAIL ADDRESS: STREET 1: TWO BETHESDA METRO CENTER STREET 2: SUITE 1300 CITY: BETHESDA STATE: MD ZIP: 20814 FORMER COMPANY: FORMER CONFORMED NAME: SEQUEL CORP DATE OF NAME CHANGE: 19890814 FORMER COMPANY: FORMER CONFORMED NAME: CELLTECH COMMUNICATIONS INC DATE OF NAME CHANGE: 19860304 4 1 cmw4356_ex.xml X0303 4 2009-06-16 0 0000722723 HANGER ORTHOPEDIC GROUP INC HGR 0001217563 SABEL IVAN R TWO BETHESDA METRO CENTER SUITE 1200 BETHESDA MD 20814 1 1 0 0 Chairman of the Board Common Stock 2009-06-16 4 S 0 13600 13.5781 D 366650 D Common Stock 1100 I Spouse's IRA Option to Buy 14.23 2003-05-30 2012-05-29 Common Stock 100000 100000 D Option to Buy 13.80 2004-08-01 2013-07-31 Common Stock 90000 90000 D The shares of common stock were sold to cover taxes incurred as a result of the vesting of restricted shares. These shares were sold at a range of sale prices from $13.22 to $13.99. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Includes (i) unvested restricted shares that total 31,350 shares of stock from an initial grant of 31,350 shares of restricted stock made on November 13, 2008; (ii) unvested restricted shares and fully vested shares that total 116,250 shares of stock from an initial grant of 155,000 shares of restricted stock and performance shares made on August 9, 2007; (iii) unvested restricted shares and fully vested shares that total 56,400 shares of stock from an initial grant of 140,000 shares of restricted stock made on June 12, 2006; and (iv) 23,250 shares of common stock that were derived from a previous grant of restricted shares that are now fully vested. All remaining unvested restricted shares will continue to vest at a rate of 25% per year of the original grant amount on the anniversary date of the grant. This option was fully vested on June 23, 2005. /s/ Teri L. Champ, Attorney-in-Fact 2009-06-18 -----END PRIVACY-ENHANCED MESSAGE-----